selurampanel Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Selurampanel is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.   Wikipedia

Chemistry

  • SMILES: CC(C)c1cc2NC(=O)N(NS(=O)(=O)C)C(=O)c2cc1c3ccnn3C
  • InChIKey: MCECSFFXUPEPDB-UHFFFAOYSA-N
  • Mol. Mass: 377.43
  • ALogP: 0.72
  • ChEMBL Molecule:
    selurampanel  
More Chemistry

Pharmacology

Alternative names

bgg492 | bgg-492 | selurampanel

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Adrenocortical Adenoma (Phase 2)

Epilepsy (Phase 2)

Epilepsy, Reflex (Phase 2)

Migraine Disorders (Phase 2)

Multiple Sclerosis (Phase 2)

Sarcoma, Endometrial Stromal (Phase 2)

Seizures (Phase 2)

Tinnitus (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue